Pig Hearts and Kidneys in Humans: The 2026 Clinical Trial Era of Xenotransplantation

For six decades, xenotransplantation — using non-human organs in human recipients — was a field of ambitious experiments and crushing failures. The immune rejection was instant, brutal, and effectively unsolvable with the tools we had. In 2026 that changed. The FDA cleared the first two US clinical trials of gene-edited pig kidneys in humans, run by United Therapeutics and eGenesis. The era of compassionate-use case reports is ending and the era of structured trials is beginning.

This piece walks through what xenotransplantation actually is, how decades of gene editing made it plausible, what the early single-patient experiences taught us, and what the new trials are designed to answer.

The transplant waitlist problem

In the United States alone, roughly 100,000 people are on the kidney transplant waitlist at any given time. Many will not receive an organ before their disease becomes terminal. The supply of human donor organs has been growing, but not nearly fast enough to close the gap. Xenotransplantation is the only realistic supply-side answer — a renewable, scalable source of organs that could in principle outstrip demand.

Why the pig — and why this generation of pig

Pigs are anatomically compatible with humans, breed quickly, and can be raised under controlled conditions. The problem has always been the immune mismatch. Pig cells display surface sugars — α-Gal, Neu5Gc, SDa — that human immune systems recognise as foreign and attack within minutes. The first decade of CRISPR work tackled exactly this: knock out the genes responsible for those sugars so the resulting pigs produce organs that look less alien.

What happened before the trials

The first transplants of these organs into living humans were not clinical trials in the traditional sense. They were emergency compassionate-use cases, performed under the FDA''s expanded access pathway in patients who had no other options.

• March 2024 — Massachusetts General Hospital. The first transplant of a gene-edited pig kidney into a living person. The recipient received an eGenesis kidney; outcomes were closely monitored.
• April 2024 — Langone Health, NJ. A woman received a pig kidney and a pig heart pump (with the heart explanted and human transplanted later). The kidney was removed at day 47 because it was failing.
• 2022–2024 — University of Maryland. Two pig heart transplants into terminally ill patients. Both recipients died within two months. Postmortem analysis pointed to immune complications and possible viral contamination from the donor pig.

These are not the failures the field hides from. They are the data that shaped the 2026 trial designs.

What the new trials will actually test

The UKidney and eGenesis kidney trials begin with carefully selected patients — typically on dialysis, with a low chance of receiving a human kidney through conventional channels. Both trials are open-label Phase 1 studies designed to assess safety, immunological response, and organ function over months rather than weeks. Heart xenotransplantation is following a more cautious trajectory; survival in non-human primates with the 69-edit organs has only recently reached the one- to two-year mark.

The hard problems that remain

Immune rejection is no longer the only concern. Patients need lifelong immunosuppression on top of the host of medications transplant recipients already take. Infectious risk includes not just standard opportunistic infections but the theoretical possibility of porcine viruses crossing into humans — which is why PERV inactivation matters in the eGenesis design. And the regulatory framework for animal-sourced organs is still being written in real time, with shifting requirements for donor pig facilities, biocontainment, and long-term surveillance of recipients.

There is also a quieter ethical question. If xenotransplantation works at scale, will the cost structure favour wealthy countries and wealthy patients first? The early answer is yes — these are expensive organs from expensive facilities — but that is true of any frontier medicine.

What students should take from this moment

Xenotransplantation is a useful illustration of how multiple technologies have to mature together for a single clinical advance. Multiplex CRISPR editing (10 simultaneous targeted changes was once unthinkable), modern immunosuppression, donor-animal biocontainment, transplant surgery, and regulatory science all had to converge. None of them on their own was enough. The same convergence pattern is now showing up in cell therapy, in vivo gene editing, and personalised cancer vaccines.